Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01200992 2017-08-24

EMBARC-RF

Phase 3 Terminated

84 enrolled 7 charts

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT02254915 2015-04-01

SHTC-EUROPE-1

Phase 3 Withdrawn

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT00384891 2014-10-07

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Phase 3 Terminated

190 enrolled

Genitourinary

Hyperthermia, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Neoplasms by Site, Urologic Diseases, Urologic Neoplasms

Clinical Trials

Savolitinib vs. Sunitinib in MET-driven PRCC.

BOOST

RESCUE

RESCUE

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

JAVELIN Bladder 100

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

EMBARC-RF

SHTC-EUROPE-1

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer